MHRA Safety Roundup April 2025

View as a webpage / Share

MHRA Safety Roundup

April 2025

MHRA Safety Roundup: April 2025

This month's MHRA Safety Roundup includes:

Drug Safety Update on Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk
Drug Safety Update on Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Letters, medicines recalls and device notifications sent to healthcare professionals in March and April 2025
News on BCR-ABL tyrosine kinase inhibitors and interstitial lung disease, new guidance on risk minimisation materials, update to UK clinical trials

April's Safety Roundup is now available to read as a downloadable document or on the GOV.UK website.

It's easy to report

Report a suspected adverse drug reaction online
or download the Yellow Card app

REPORT ONLINE

Thank you,

The Medicines and Healthcare products Regulatory Agency

If you would like to share this with a friend or colleague, hit the Forward button or send them this link to view the email in a browser.

Unsubscribe or change your email address at any time on your subscriber preferences page.

If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

All other enquiries can be directed to email.support@mhra.gov.uk.

This is an automatically generated email. Please do not reply directly to this notification.
This service is provided to you at no charge by the Medicines and Healthcare products Regulatory Agency.